The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Medpace (MEDP) reported earnings 30 days ago. What's next for the stock?
Medpace (MEDP) possesses solid growth attributes, which could help it handily outperform the market.
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
Curtis Ellergodt Rothschild Investment LLC | 1,228 | $644,930.05 | $718,392.28 | $73,462.23 | 11.39% |
| BZ Brandon Zatopek Commonwealth Equity Services LLC | 3,469 | $1.84M | $2.05M | $211,887.16 | 11.53% |
| BS Barrett Schultz Ashton Thomas Securities LLC | 471 | $241,693.59 | $271,818.81 | $30,125.22 | 12.46% |
| ABB Alexander Bjornager Bonde Danske Bank A/S | 20 | $11,233 | $11,801.6 | $568.6 | 5.06% |
| JD Jim Dushek HARBOUR INVESTMENTS Inc. | 54 | $26,868.86 | $32,697 | $5,828.14 | 21.69% |
| Professional Services Industry | Industrials Sector | August James Troendle CEO | NASDAQ (NGS) Exchange | 58506Q109 CUSIP |
| US Country | 6,500 Employees | - Last Dividend | - Last Split | 11 Aug 2016 IPO Date |
Medpace Holdings, Inc., founded in 1992 and headquartered in Cincinnati, Ohio, is a key player in the provision of comprehensive clinical research services for the development of drugs and medical devices. Spanning its operations across North America, Europe, and Asia, the company supports pharmaceutical, biotechnology, and medical device industries through the entire clinical development process, from Phase I to Phase IV, across a wide range of therapeutic areas. Its aim is to facilitate the journey of bringing new and innovative treatments to market efficiently and effectively.